BMEA Biomea Fusion, Inc.
Healthcare · Market cap: $42.2M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $86.8K | $0 |
| 2022-Q2 | $0 | $407.6K |
| 2022-Q3 | $0 | $388.5K |
| 2022-Q4 | $70.9K | $0 |
| 2023-Q1 | $12.0M | $6.2M |
| 2023-Q2 | $0 | $19.5M |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $0 | $0 |
| 2024-Q1 | $0 | $0 |
| 2024-Q2 | $55.4K | $0 |
| 2024-Q3 | $100.6K | $0 |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $0 |
| 2025-Q2 | $0 | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $196.4K | $0 |
| 2026-Q1 | $0 | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $0 | $0 |
Bought$12.5M10 buy days
Sold$26.6M9 sell days
Net insider flow-$14.0Mnet selling · 5 years
Latest trade2025-12-11Erdtmann Rainer M
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | Buy | Erdtmann Rainer M | Director | 30,000 | $1.43 | $42.9K | 1 |
| 2025-12-02 | Buy | Hitchcock Michael J.M. | CEO | 100,000 | $0.99 | $99.0K | 1 |
| 2025-12-01 | Buy | Erdtmann Rainer M | Director | 10,000 | $1.05 | $10.5K | 1 |
| 2025-11-28 | Buy | Erdtmann Rainer M | Director | 40,000 | $1.10 | $44.0K | 1 |
| 2024-09-30 | Buy | Hitchcock Michael J.M. | Director | 10,000 | $10.06 | $100.6K | 1 |
| 2024-06-11 | Buy | Valle Franco | CFO | 12,509 | $4.43 | $55.4K | 1 |
| 2023-06-01 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 50,000 | $34.56 | $1.7M | 1 |
| 2023-05-31 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 75,000 | $33.81 | $2.5M | 1 |
| 2023-05-12 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 25,000 | $33.84 | $846.0K | 1 |
| 2023-05-09 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 150,000 | $34.50 | $5.2M | 1 |
| 2023-05-08 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 100,000 | $33.99 | $3.4M | 1 |
| 2023-04-20 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 200,000 | $29.12 | $5.8M | 1 |
| 2023-03-31 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 200,000 | $31.25 | $6.2M | 1 |
| 2023-03-30 | Buy | Chen Bihua | Director | 400,000 | $30.00 | $12.0M | 1 |
| 2022-11-14 | Buy | Hitchcock Michael J.M. | Director | 5,000 | $7.93 | $39.6K | 1 |
| 2022-11-11 | Buy | Valle Franco | CFO | 4,100 | $7.63 | $31.3K | 1 |
| 2022-07-21 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 34,658 | $11.21 | $388.5K | 1 |
| 2022-06-24 | Sell | A2A Pharmaceuticals, Inc. | 10% owner | 34,658 | $11.76 | $407.6K | 1 |
| 2022-01-14 | Buy | Valle Franco | CFO | 10,000 | $8.68 | $86.8K | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| A2A Pharmaceuticals, Inc. | 10% owner | $0 | $26.6M | 2023-06-01 |
| Chen Bihua | Director | $12.0M | $0 | 2023-03-30 |
| Hitchcock Michael J.M. | CEO | $239.2K | $0 | 2025-12-02 |
| Valle Franco | CFO | $173.5K | $0 | 2024-06-11 |
| Erdtmann Rainer M | Director | $97.4K | $0 | 2025-12-11 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2021-08-17 → 2021-09-17 | 4 | $2.0M | 65 | +0.8% (+5.2% raw) | -25.9% (-25.6% raw) | -47.5% (-53.7% raw) | closed |
| 2021-04-15 → 2021-04-20 | 3 | $21.4M | 51 | -6.6% (-7.7% raw) | -3.3% (+3.8% raw) | -41.8% (-42.5% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.